New combo therapy aims to control prostate cancer spread without lifelong drugs
Disease control
Completed
This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to targeted radiation could help control prostate cancer that has spread to a few places in the body. Twenty-three men with newly diagnosed, hormone-sensitive prostate cancer took part. The goal was …
Phase: PHASE2 • Sponsor: David Oh • Aim: Disease control
Last updated May 13, 2026 16:01 UTC